FCGR3A and neoplasm: Several studies have shown that those individuals that are homozygous for V (FcγRIIIA-158-V/V) have improved clinical outcome (after treatment with ADCC-inducing tumor-reactive mAb) over those that are either heterozygous (FcγRIIIA-158-V/F) or homozygous (FcγRIIIA-158-F/F) for the lower affinity FcγRIIIA isoform (42–46).